Add
PTX to Portfolio
Set Alert
Email to a
Friend
| |||
|
|
Quotes & Info
|
| PTX > SEC Filings for PTX > Form 8-K on 24-Jan-2013 | All Recent SEC Filings |
24-Jan-2013
Change in Directors or Principal Officers, Other Events, Finan
On January 17, 2013, David Becker informed the Company that he will resign as Chief Financial Officer of Pernix Therapeutics Holdings, Inc. (the "Company"), due to personal reasons, effective March 31, 2013. Mr. Becker will be paid his current base salary through the effective date of his resignation. Mr. Becker has agreed to continue in a consulting role with the Company following his resignation.
On January 18, 2013, Charles Hrushka stepped down as Vice President of Sales & Marketing of the Company effective immediately. Mr. Hrushka will be paid his current base salary through the effective date of his resignation. Mr. Hrushka has agreed to continue in a consulting role with the Company.
On January 24, 2013, the Company issued a press release announcing the restructuring and integration of the Company's sales force following its acquisition of Cypress Pharmaceuticals, Inc. and Hawthorn Pharmaceuticals, Inc. on December 31, 2012. The full text of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
(d) Exhibits.
Exhibit
Number Description
99.1 Press release by Pernix Therapeutics Holdings, Inc. dated
January 24, 2013
|
|
|